Lomond terminates menin inhibitor license from Bala; receives 3.5% stake

Lomond Therapeutics Holdings, Inc.

Terminated license agreement with Bala for an early-stage menin inhibitor (AML) due to crowded competitive landscape.
Company had spent ~$600K on development; $1.2M deferred payment obligation cancelled with termination.
Received 111,585 shares of Bala common stock (~3.5% of fully diluted cap) as consideration for prior expenditure.
All licensed IP reverts to Bala; no further development or payments required.
No activities or third-party agreements had been undertaken under the license.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Lomond Therapeutics Holdings, Inc. terminated License Agreement with Bala Therapeutics, Inc. valued at Terminated agreement with consideration including shares representing 3.5% fully diluted capitalizat (effective 2026-01-07).

Action: termination
Agreement: license
Counterparty: Bala Therapeutics, Inc.
Value: Terminated agreement with consideration including shares representing 3.5% fully diluted capitalizat
Effective: 2026-01-07

Exact text from the filing

On January 7, 2026, Lomond Therapeutics, Inc. (the "Company") entered into a Termination Agreement with Bala Therapeutics, Inc. ("Bala"), pursuant to which that certain License Agreement, dated October 17, 2024, by and between the Company and Bala (the "License Agreement"), was terminated ab initio , effective immediately.

View on SEC.gov

294 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR

accession 0001213900-26-003905

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.